Teverelix-TFA Lyophilizate Gel Prevention Process
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The existing lyophilization processes for teverelix-TFA are inefficient due to gel formation, batch variations in molar ratios, instability during storage, and the need for strong acids, which affect bioavailability and require specialized equipment, leading to high costs and complexity.
Innovation Solution
A novel lyophilization process that uses a molar ratio of teverelix to trifluoroacetate of at least 1:2.1 to prevent gel formation, eliminates the need for strong acids, and includes centrifugation or filtration to adjust the molar ratio, resulting in a stable, sterile teverelix-TFA lyophilizate with higher concentrations and extended shelf life.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Stability of the object's composition
If the molar ratio of teverelix to trifluoroacetate is at least 1:1.6 as disclosed in WO 2003/022243, then gel formation is prevented, but batch variations in molar ratio occur and bioavailability is compromised
Solution Approach 1:
The patent changes the molar ratio parameter from the previously disclosed 1:1.6 to a new range of 1:2.0 to 1:3.0. This parameter change resolves the contradiction by providing a new optimal ratio that simultaneously prevents gel formation and ensures batch-to-batch consistency, thereby improving both stability and reliability of the formulation.
Solution Approach 2:
The patent implements quality control measures that monitor and adjust the molar ratio during manufacturing. By establishing feedback mechanisms to ensure the molar ratio falls within the 1:2.0 to 1:3.0 range, the process achieves consistent bioavailability across batches while maintaining gel prevention, thus resolving the reliability-stability contradiction.
2Ease of manufacture
If strong acids are used to dissolve teverelix-TFA for lyophilization, then dissolution is achieved, but specialized equipment is required and costs increase
Solution Approach 1:
The patent uses trifluoroacetate as an intermediary substance that enables dissolution of teverelix without requiring strong acids. The trifluoroacetate forms a soluble complex with teverelix, allowing standard lyophilization equipment to be used. This intermediary approach resolves the contradiction by achieving dissolution capability while eliminating the need for specialized equipment.
Solution Approach 2:
The patent replaces expensive specialized equipment requirements with a chemical solution (trifluoroacetate) that can be used with standard, widely available lyophilization equipment. This substitution of chemical intermediary for equipment complexity reduces manufacturing costs and device requirements while maintaining dissolution capability.
3Duration of action of moving object
If teverelix is formulated for sustained release, then hormone-dependent conditions are treated, but gel formation limits use and bioavailability
Solution Approach 1:
The patent changes the molar ratio parameter to 1:2.0 to 1:3.0, which fundamentally alters the formulation's physical properties. This parameter change prevents gel formation while maintaining sustained release capability, resolving the contradiction between duration of action and compositional stability by finding an optimal ratio that avoids gelation.
Solution Approach 2:
The patent creates a composite formulation of teverelix and trifluoroacetate at specific molar ratios that combines the sustained release properties of the peptide with the gel-preventing properties of the counter-ion. This composite approach resolves the contradiction by integrating both functionalities into a single stable formulation.
4Ease of operation
If teverelix-TFA is stored at refrigeration or room temperatures, then accessibility is improved, but stability decreases and shelf life is shortened
Solution Approach 1:
The patent changes the formulation parameters, specifically the molar ratio of teverelix to trifluoroacetate, to create a composition that is stable at higher temperatures. This parameter change resolves the contradiction by enabling storage at refrigeration or room temperatures without compromising shelf life, thus improving accessibility while maintaining stability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves a stable, sterile teverelix-TFA lyophilizate with higher concentrations, reduced costs, and improved bioavailability, allowing for easier reconstitution and administration, while eliminating the need for filter sterilization and specialized equipment.
Implementation Method 1
Lyophilization (freeze drying) is a widely used process for improving the stability of pharmaceuticals
Implementation Method 2
the material is freeze-dried over night
Implementation Method 3
includes centrifugation or filtration to adjust the molar ratio
Data Source
AI summary
The present invention relates to a lyophilization process for preparing a teverelix-TFA lyophilizate, said process comprises the following steps: a) providing a lyophilization suspension by mixing teverelix and trifluoroacetate at a molar ratio sufficient for providing a microcrystalline teverelix-TFA suspension without formation of a gel, and b) lyophilizating the lyophilization suspension, thereby providing a teverelix-TFA lyophilizate. The process provides the possibility of obtaining a “pure” teverelix-TFA lyophilizate i.e. without any undesirable residues in the composition.